Peter Stopfer
Impact in
- Pharmacology top 1%
- Pharmacogenetics and Drug Metabolism
-
- Lung Cancer Treatments and Mutations
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Papers in
- Pharmacology 19
- Pharmacogenetics and Drug Metabolism 19
- Oncology 28
- HER2/EGFR in Cancer Research 13
- Drug Transport and Resistance Mechanisms 11
- Colorectal Cancer Treatments and Studies 4
- Co-authors
- Thomas Ebner (9 shared papers)Sven Wind (8 shared papers)Rolf Kaiser (9 shared papers)Kristell Marzin (5 shared papers)Matthias Freiwald (3 shared papers)Dietmar Ganßer (6 shared papers)Daniela N. Männel (5 shared papers)Thomas Hehlgans (5 shared papers)
- Journals
- Clinical Pharmacokinetics (6 papers)Annals of Oncology (4 papers)Cancer Chemotherapy and Pharmacology (4 papers)Clinical Pharmacology & Therapeutics (4 papers)Investigational New Drugs (3 papers)
- Partner nations
- GermanyUnited StatesJapan
In The Last Decade
Peter Stopfer
51 papers receiving 2.5k citations
Peers
Comparison fields: 5 of 85
- Pharmacology 367
- Pulmonary and Respiratory Medicine 1k
- Oncology 658
- Immunology 157
- Analytical Chemistry 73
Countries citing papers authored by Peter Stopfer
This map shows the geographic impact of Peter Stopfer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Stopfer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Stopfer more than expected).
Fields of papers citing papers by Peter Stopfer
This network shows the impact of papers produced by Peter Stopfer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Stopfer. The network helps show where Peter Stopfer may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Stopfer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 52 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 313 | |
| 2 | 2007 | 215 | |
| 3 | 2016 | 161 | |
| 4 | 2019 | 160 | |
| 5 | 2009 | 153 | |
| 6 | 2011 | 130 | |
| 7 | 2011 | 118 | |
| 8 | 2010 | 85 | |
| 9 | 2013 | 80 | |
| 10 | 2016 | 70 | |
| 11 | 2011 | 69 | |
| 12 | 2012 | 66 | |
| 13 | 2004 | 60 | |
| 14 | 2014 | 56 | |
| 15 | 2009 | 54 | |
| 16 | 2004 | 53 | |
| 17 | Lymphotoxin-beta receptor immune interaction promotes tumor growth by inducing angiogenesis. | 2002 | 49 |
| 18 | 2016 | 49 | |
| 19 | 2014 | 46 | |
| 20 | 2020 | 46 |
About Peter Stopfer
Peter Stopfer is a scholar working on Pharmacology, Oncology, Pulmonary and Respiratory Medicine, Pediatrics, Perinatology and Child Health and Immunology, having authored 52 papers that have together received 2.6k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (19 papers), HER2/EGFR in Cancer Research (13 papers), Drug Transport and Resistance Mechanisms (11 papers), Lung Cancer Treatments and Mutations (10 papers), Angiogenesis and VEGF in Cancer (5 papers), Colorectal Cancer Treatments and Studies (4 papers), Pharmaceutical studies and practices (4 papers) and Inflammatory Bowel Disease (2 papers). The work is most often cited by research in Pharmacology (367 citations), Pulmonary and Respiratory Medicine (1k citations), Oncology (658 citations), Immunology (157 citations) and Analytical Chemistry (73 citations). Peter Stopfer has collaborated with scholars based in Germany, United States and Japan. Frequent co-authors include Thomas Ebner, Sven Wind, Rolf Kaiser, Kristell Marzin, Matthias Freiwald, Dietmar Ganßer, Daniela N. Männel, Thomas Hehlgans, Martina Uttenreuther‐Fischer and Mehdi Shahidi. Their work appears in journals such as Clinical Pharmacokinetics, Annals of Oncology, Cancer Chemotherapy and Pharmacology, Clinical Pharmacology & Therapeutics and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.